Anebulo Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse , today announced.
FDA provides favorable input on studies to support ANEB-001 approval
Part C Extension of Phase 2 trial completed exploring THC challenge dose of up to 60 mg
.